天眼查App显示，近日，四川之江小象医疗科技有限公司成立，法定代表人为杨平号，注册资本1000万 人民币，由四川数智小象科技有限公司全资持股。 序号股东名称持股比例1四川数智小象科技有限公司100% 经营范围含技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；信息系统集成服务；网 络与信息安全软件开发；移动终端设备销售；通讯设备销售；电子产品销售；物联网技术服务；信息技 术咨询服务；数据处理服务；国内贸易代理；货物进出口；智能控制系统集成；国内货物运输代理；卫 星移动通信终端销售；第一类医疗器械销售；医用口罩批发；医用口罩零售；医护人员防护用品批发； 医护人员防护用品零售；日用口罩（非医用）销售；劳动保护用品销售；特种劳动防护用品销售；第二 类医疗设备租赁；第一类医疗设备租赁；移动通信设备销售；健康咨询服务（不含诊疗服务）；计算机 及通讯设备租赁；计算机系统服务；软件销售；软件开发；数据处理和存储支持服务；仓储设备租赁服 务；普通货物仓储服务（不含危险化学品等需许可审批的项目）；技术进出口；第二类医疗器械销售； 护理机构服务（不含医疗服务）；人工智能基础软件开发；人工智能理论与算法软件开发；人工智能 ...

Group 1: Event Overview - The 27th China Beijing International Science and Technology Industry Expo successfully concluded on May 11, featuring the theme "Technology Leads to a Creative Future" with six specialized exhibition areas [1] - Over 800 domestic and foreign enterprises and institutions participated in the expo, showcasing various innovative achievements [1] Group 2: AI Integration in Healthcare - AI technology's deep integration with healthcare was a highlight, with surgical robots enhancing grassroots medical capabilities and enabling more precise pain management [1][2] - Stronglink Intelligent Technology Co., Ltd. demonstrated an AI catheter shaping robot for neurointerventional surgery, which assists in path planning and shaping, providing a "navigation" system for surgeons [4] Group 3: Innovations in Pain Management - Beijing New Cloud Medical Technology Co., Ltd. introduced two innovative products, including the AI closed-loop rechargeable spinal cord stimulation system (NewStim), which improves pain management by automatically adjusting stimulation parameters based on nerve feedback [5] - The advancements in AI are expected to allow for earlier intervention and treatment of potential health issues by analyzing spinal cord nerve signals [6] Group 4: Domestic Production and Replacement - The medical industry is making significant strides towards self-sufficiency, with some companies achieving full domestic production and others breaking foreign monopolies in key areas [6] - Beijing Maidis Medical Technology Co., Ltd. showcased an ultrasound-guided electromagnetic positioning puncture device, achieving a 99% success rate in puncture procedures with all components domestically produced [10] Group 5: International Expansion of Innovative Products - Koya Medical Technology Co., Ltd. presented a non-invasive coronary heart disease diagnostic product, the AI coronary CT blood flow reserve measurement, which has received multiple international certifications [14] - The product aims to shift coronary heart disease diagnosis from invasive to non-invasive methods, reducing unnecessary invasive checks [14] - Guanchuan Intelligent Technology Co., Ltd. introduced smart elderly care products that have been exported to several countries, demonstrating strong international competitiveness in both price and technology [15]

Core Viewpoint - The report summarizes the sponsorship work of Shenwan Hongyuan Securities for Suzhou Mediston Medical Technology Co., Ltd. during its non-public offering of A-shares in 2022, highlighting the company's operational challenges and compliance with regulatory requirements [1][3]. Group 1: Company Overview - Company Name: Suzhou Mediston Medical Technology Co., Ltd. [1] - Stock Code: 603990 [1] - Registered Capital: 306.2827 million yuan [1] - Legal Representative: Weng Kang [1] - Actual Controller: State-owned Assets Supervision and Administration Office of Mianyang City [1] - Listing Date: January 3, 2023 [1] - Annual Report Disclosure Date: April 30, 2025 [1] Group 2: Sponsorship Work Overview - Shenwan Hongyuan acted as the sponsor for Mediston's 2022 non-public offering, with representatives Gong Can and Ye Wenwen responsible for ongoing supervision [1][3]. - The supervision period lasted until December 31, 2024, during which the sponsor focused on enhancing the company's operational standards and internal control systems [1][3]. Group 3: Financial Performance and Challenges - In 2023, the company reported a net profit of -26.94194 million yuan, a year-on-year decline of 902.79% [3]. - For 2024, the projected operating revenue is 46.40689 million yuan, down 24.93% year-on-year, with a net profit of -27.94747 million yuan, a decrease of 3.73% [3]. - The losses are attributed to the company's new photovoltaic business, which faced supply-demand mismatches and price fluctuations, leading to operational inefficiencies [3]. Group 4: Compliance and Cooperation - The company complied with legal and regulatory requirements for information disclosure and maintained good communication with the sponsor [4][5]. - The sponsor noted that the company effectively managed its fundraising and adhered to the dedicated account storage system for raised funds, ensuring no misuse of funds occurred [5][6]. Group 5: Conclusion on Fund Usage - The sponsor concluded that the company's use of raised funds was in strict accordance with regulations, with no violations reported during the supervision period [5]. - As of December 31, 2024, all funds from the 2022 non-public offering had been fully utilized, with no outstanding matters [5].

Important Market News - The high-level economic and trade talks between China and the U.S. were held in Geneva from May 10 to 11, resulting in substantial progress and important consensus on mutual economic concerns [1] Industry Insights - On May 11, the humanoid robot startup Songyan Power launched a new generation of bionic robot named Xiao Nuo, featuring multi-modal interaction and near-human facial expressions. The company has already secured over 1,000 orders for its N2 robot, which has gained attention for its performance in various terrains [2] - The introduction of 5G-A technology is being noticed by consumers in cities like Beijing and Shanghai, enhancing communication capabilities significantly compared to 5G. The expected investment in 5G-A in China is projected to reach 120 billion yuan by 2025, driving growth in related industries [3] - A new online platform for "brain-computer interface patents and intellectual property" was launched at the 2025 Pujiang Innovation Forum, marking a significant step in the commercialization of brain-computer interface technology, with a market potential projected to reach $150 billion by 2040 [4] - The State Council approved the draft of the "Regulations on Government Data Sharing," aiming to enhance public service efficiency and promote the integration of data resources, which is expected to benefit cloud computing and big data platform companies [5][6] Risk Alerts - Xi'an Qujiang Cultural Tourism announced that its major shareholder's 12 million shares will be auctioned, representing 10.48% of its holdings and 4.7% of the company's total shares, although this will not affect the company's operations [7] - Keli Ke plans to reduce its shareholding by up to 14.647 million shares, accounting for 3% of the total shares, while other executives also plan to sell a small percentage of their shares [8]

"健养安-安心股养"签约仪式。 深圳赛陆医疗科技有限公司作为建设银行"健养安-安心股养"首批签约拟上市企业，立足世界科技前沿，以国家战略需求为指导，自主创新为核心动力，全 力推动基因测序和空间组学技术的革新与发展，是国产基因测序仪领军企业，获深创投等知名创投机构投资。建行深圳市分行结合企业持股平台架构及上市 进程，为企业量身定制"股权激励+上市服务+金融授信"综合服务方案，为科创企业提供全链条、场景化的养老金融服务。 在当天的揭牌仪式上，建行深圳市分行邀请深圳市慈善会执行副会长、八卦岭社区书记及银发客户共同为建行深圳市八卦岭支行揭牌。至此，深圳地区已挂 牌2家"健养安"养老金融特色网点，深圳建行养老金融服务体系再升级。 转自：新华财经 5月8日，中国建设银行在福建省福州市举办"健养安"养老金融特色网点扩容升级发布会暨养老金融产品服务推介会，并集中揭牌全国第二批"健养安"养老金 融特色网点。建设银行副行长纪志宏出席活动并致辞。中国建设银行深圳市分行（以下简称建行深圳市分行）资深副经理刘星，深圳赛陆医疗科技有限公司 联合创始人、CTO刘二凯参加"健养安-安心股养"股权激励增值服务现场签约。建行深圳市分行第二批"健 ...

Group 1: Robotics Innovations - The "Tiangong" robot, showcased at the Yizhuang exhibition area, is the world's first "human-machine co-running" half marathon champion, with its sibling "Tiangong 2.0" set to be released, featuring advanced capabilities for complex terrain navigation [1] - The Walker S1 humanoid robot from UBTECH is designed for general tasks, utilizing advanced technologies such as multimodal planning and semantic VSLAM, enhancing its agility and intelligence for industrial applications [1] Group 2: Medical Technology Advancements - Changmu Valley Medical Technology Co., Ltd. introduced the ROPA orthopedic intelligent surgical robot system, which is the first to achieve "integrated diagnosis and treatment" in orthopedic AI surgery, addressing the dependency on imported technologies [2] Group 3: Aerospace and Quantum Computing Breakthroughs - Beijing Xingtu Zhili Technology Co., Ltd. launched the "Netling Satellite Internet Terminal," the first domestically produced satellite communication device for civilian use, which was successfully deployed during the 2025 Myanmar earthquake rescue [2] - The new generation coherent optical quantum computer from Beijing Boson Quantum Technology Co., Ltd. has surpassed the 1000-bit scale, offering exponential computational power compared to classical computers, significantly reducing processing time in drug discovery [3] Group 4: Overall Impact of the Expo - The Beijing International Science and Technology Industry Expo serves as a platform for showcasing technological achievements, facilitating the transformation of scientific results and promoting collaborative industrial development [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 会议召开时间：2025年05月16日(星期五) 下午 13:15-14:45 ● 会议参与方式一：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/）； 会议参与方式二："麦迪科技投资者关系"小程序，通过微信搜索"麦迪科技投资者关系"或微信扫一扫以 下二维码参与会议 副董事长、总经理翁康先生；独立董事李东先生；副总经理、董事会秘书李孟豪先生；财务总监梅皓先 生。 四、 投资者参加方式 （一）投资者可在2025年05月16日下午13:15-14:45，通过互联网登录上证路演中心 ● 会议召开方式：视频直播和网络互动 ● 投资者可于2025年05月09日(星期五)至05月15日(星期四)16:00前登录上证路演中心网站首页点击"提问 预征集"栏目或通过公司邮箱suzhoumedi001@medicalsystem.cn进行提问。公司将在说明会上对投资者普 遍关注的问 ...

Group 1 - The company, Yaoshi Bang (9885.HK), has initiated a share buyback program, repurchasing 300,000 shares for approximately HKD 2.104 million at an average price of HKD 7.0147 per share, with plans to utilize up to HKD 1 billion for further buybacks by October 31, 2025, indicating positive expectations for its performance and market future [1][2] - The company's financial performance has shown significant improvement, with a reported revenue of HKD 17.904 billion for 2024, representing a year-on-year growth of 5.5%, and a net profit of HKD 157 million, up 20.1%, marking its first annual profit [1] - The company has demonstrated strong cash flow management, with inventory turnover days at only 31 days and a cash cycle of -28.9 days, highlighting its effective inventory and cash management practices [1] Group 2 - The company is characterized as a "cigar butt stock" due to its stable operations and abundant cash flow, which are currently undervalued in the market, attracting attention from public funds [2] - Analysts suggest that the potential for short-term valuation recovery exists, as the stock price may revert to its intrinsic value with improved market sentiment or industry conditions, while quality companies can achieve long-term value enhancement through operational improvements [2] - With ongoing domestic policy support for optimizing grassroots medical resource allocation, companies like Yaoshi Bang, which have a digitalization advantage, are expected to enter a rapid development phase, creating opportunities for medium to long-term investments [2]

Group 1 - The core business of the company is providing Clinical Information System (CIS) software and overall solutions for clinical medical management [2] - The company's main product, DoCare, covers critical areas such as operating rooms, intensive care units, pre-hospital emergency care, and in-hospital emergency services [2] - The company has a user base of over 2,400 medical institutions across 32 provinces, including nearly 1,200 tertiary hospitals [2] Group 2 - As of March 31, 2025, the number of shareholders increased by 11,318 to a total of 48,361, with an average holding value of 352,800 yuan per shareholder [1] - The latest financial report for Q1 2025 shows a revenue of 63.34 million yuan, a year-on-year decrease of 43.13%, while net profit increased by 138.55% to 23.60 million yuan [3] - The company has a current market capitalization of 4.554 billion yuan and a price-to-book ratio of 5.53 [1][4]

Group 1: Tesla Developments - Tesla plans to release an unsupervised version of its Full Self-Driving (FSD) feature within a few months, with testing starting in Austin in June and rapid rollout across the U.S. [4] - The company aims for future manual driving to become as rare as horseback riding, indicating a significant shift in transportation norms [4] Group 2: Robotics and AI Innovations - Tesla is developing a humanoid robot named Optimus, which is expected to assist individuals in various tasks, representing a substantial market opportunity [4] - The AI system Grok has been developed to perform complex analyses accurately, emphasizing the importance of instilling a truth-seeking value in AI for safety [9] Group 3: SpaceX and Multiplanetary Goals - SpaceX focuses on rocket launches and Starlink internet operations, with ambitions to develop technologies that enable human survival on other planets, particularly Mars [6] Group 4: Neuralink's Medical Advancements - Neuralink is working on a brain-machine interface device called "Mind Reading," allowing paralyzed patients to control devices using thoughts, with current users able to communicate via the X platform [6] - A second device, "Blind Vision," aims to restore sight to blind individuals by connecting directly to the visual cortex, with initial surgeries expected within the next year [8] - The company is optimistic about enabling individuals with spinal cord injuries to regain mobility by bridging signals from the brain to damaged areas of the spine [8] Group 5: Legacy and Vision - The company aims to leave a legacy of advancing civilization, enhancing knowledge, and helping humanity understand the universe [11]